Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide versus prednisolone after liver transplantation
ACTRN12623000340639Phase 3Active, not recruiting
- Sponsor
- Austin Health
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and prednisolone in organ allograft rejection, sponsored by Austin Health. Primary endpoint: Rate of liver biopsy-proven acute cellular rejection. Started Aug 2023; status: active, not recruiting.
02
Drugs
budesonideprednisolone
03
Conditions
organ allograft rejection
Beyond the preview
Go deeper on ACTRN12623000340639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000340639.